key: cord-0975911-mu052nir
authors: León-Jiménez, A.; Vázquez-Gandullo, E.; Montoro-Ballesteros, F.
title: Pulmonary toxicity by oxygen and COVID-19()
date: 2022-04-28
journal: Med Intensiva (Engl Ed)
DOI: 10.1016/j.medine.2022.04.004
sha: 8c950f8b7ee879d0fb43c91740335ee7bf3b4b4c
doc_id: 975911
cord_uid: mu052nir

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 

Los autores declaran no tener ningún conflicto de intereses.

Pulmonary toxicity by oxygen has been known for over a century. Exposure to a fraction of inspired oxygen (FiO2) of 0.7 causes progressive pulmonary lesion and the intensity of the lesions is associated with the concentration and duration of hyperoxia. 1 Lesion manifests just a few hours after the administration of oxygen in high concentrations causing an increased alveolar-capillary patency and a complex cellular response including epithelial, endothelial, proinflammatory cells, and platelets that induce the destruction of alveolocapillary membranes with increased air spaces, vascular obstruction due to microthrombi, and cellular infiltration that eventually leads to the loss of alveolar architecture and, in the long run, to pulmonary fibrosis. All oxygen-induced lesions are similar to those due to acute respiratory distress syndrome (ARDS). Also, in patients with established ARDS, hyperoxia can worsen clinical results. 2 Finally, many of the pathological characteristics reported in hyperoxia occur also in ARDS due to COVID-19 since it has been reported that in these patients' lungs increased air spaces following the destruction of alveolar septa, alveolar swelling, capillary thrombosis, perivascular infiltrates, and fibrosis have been found. 3 The appearance of COVID19 has challenged respiratory support, and the need for applying elevated fractions of inspired oxygen has been a constant in many patients whether through high-flow nasal oxygen (HFNO) therapy or concomitantly to ventilation systems. However, the high mortality rates reported in cases of ARDS-an average of 39%-is indicative that, at least in some cases, the application of elevated concentrations of oxygen is worsening or triggering COVID-19 3 -related ARDS-like lesions. It could even cause a vicious circle that would create the need to increase the concentration of oxygen gradually in the air breathed in thus causing greater pulmonary impairment.

This possibility-together with data obtained by other authors 4 that most patients with moderate-to-severe acute respiratory failure due to COVID-19, and even cases with radiological findings and compatible gas exchange with ARDS recovered with CPAP and FiO2 between 0.4 and 0.6, should, in own opinion, make us reconsider or detail the current strategy of respiratory support. Therefore, following the plan established by current recommendations, 5 although the next step towards conventional oxygen therapy can still be HFNO when FiO2 > 0.6 would be needed respiratory support like CPAP should be attempted to recruit more alveolar units before increasing FiO2 to levels that can be toxic to an already damaged lung. Even under certain safety and monitoring conditions, the saturation target currently established at around 95% in the aforementioned current recommendations could be reduced down to 92% to stop FiO2 from going > 0.6.

Should Oxygen Therapy Be Tightly Regulated to Minimize Hyperoxia in Critically Ill Patients? Respir Care

Oxygen exposure resulting in arterial oxygen tensions above the protocol goal was associated with worse clinical outcomes in acute respiratory distress syndrome

Hyperoxia and modulation of pulmonary vascular and immune responses in COVID-19

Covid-19 study group; collaborators of the Galliera CPAP-COVID-19 study group are. Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure